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ABSTRACT In human tissues, adenosine deaminase (ADA) (adenosine aminohydrolase; EC 3.5.4.4) activity can be separated by gel electrophoresis into several isozymes. A structural gene (ADA) on chromosome 20 codes for the "erythrocyte" isozyme, ADA-1, which is also expressed in some nonerythroid tissues. Nonerythroid cells also differentially express five ADA "tissue isozymes" of a greater molecular weight than ADA-1. Each ADA tissue isozyme has a characteristic electrophoretic mobility and tissue distribution. It has been suggested tat these ADA tissue isozymes are composed of ADA-1 and other components. We report that the expression of one of these tissue isozymes, ADA-d, is dependent upon ADA on chromosome 20 and another gene on chromosome 6 which functions in the assembly of the ADA tissue isozymes. In human-mouse hybrids segregating human chromosomes, chromosome 6+,20+ hybrids express both ADA-1 and ADA-d; chromosome 6-,20+ hybrids express only ADA-1; while 6+,20-hybrids have no human AIDA activity. ADA-d formation also occurs in vitro by self-assembly when an extract of human erythrocytes or chromosome 6-,20+ hybrids is mixed with a homogenate of chromosome 6+,20-hybrids. The gene on chromosome 6, designated ADCP, codes for an adenosine deaminase complexing protein. 4 ). This report describes the genetics and a possible mechanism of the process that controls the formation of tissue-specific isozymes of human adenosine deaminase (ADA) (adenosine aminohydrolase; EC 3.5.4.4).
Human ADA can be separated by starch gel electrophoresis into several isozymes (5), of which there are two classes: (i) erythrocyte ADA (ADA-1), the form present in erythrocytes and most other tissues, and (ii) a variety of tissue-specific isozymes (ADA-a, -b, -c, -d, and -e, in order of decreasing electrophoretic mobility) that occur in varying amounts of nonerythroid tissues. The tissue isozymes are thought to be derived from the association or assembly of ADA-1 and other, noncatalytic components (6) . A deficiency of ADA-1 has been implicated as the cause of certain autosomal recessive forms of severe combined immunodeficiency disease (SCID), an inherited defect of both T-and B-lymphocyte functions (7, 8) . Although tissue extracts from patients with SCID exhibit no ADA activity on starch gels, the characteristic tissue-specific isozymes self-assemble when SCID tissue extracts are mixed with erythrocyte lysates from unaffected individuals (6, 9) . This observation demonstrates the dependence of the tissue-specific isozymes on the presence of ADA-1.
The segregation of human chromosomes and adenosine deaminase isozymes (10) erythrocyte ADA-1 (Fig. 1, channel 2) has shifted from the initially tested major cathodal band to a less intense anodal band. ADA All enzymes were analyzed on the same homogenate of each hybrid clone. The concordant column indicates the number of clones in which the marker enzymes and the ADA-d phenotype were present or absent together. The discordant column gives the number of clones in which only ADA-d or an enzyme, but not both, was present. The chromosome assignments, gene symbols, and electrophoretic procedures for each marker enzyme have been described (19) . * Forty of these 102 clones were ADA-1-; their ability to convert ADA-1 to ADA-d was tested in vitro as described in the legend to Table 1 . t The presence of human TK was inferred since human-mouse hybrids in which the mouse parent was TK-grew in HAT medium. Information on the biochemical function of ADA complexing protein in the biogenesis of the ADA tissue isozymes comes from two lines of study. First, a "conversion factor" (Mr 73,000), purified from human lung and present in other organs that contain the tissue isozymes of ADA, combines with ADA-1 (Mr 33,000) in vitro to form an ADA of a molecular weight similar to that of the tissue isozymes (Mr 230,000) (25) . A complexing protein with similar characteristics also has been isolated from human kidney (26) . These complexing proteins are antigenically unrelated to ADA-1 (25, 26) , indicating that the tissue isozymes are not multimers consisting only of ADA-1. Second, ADA isozymes specific for each tissue can be generated by mixing hemolysates, containing only ADA-1, with various tissue extracts from those patients with SCID who are grossly deficient in all ADA activities (6, 9) . These assembly components in SCID tissues, the complexing proteins from human tissues, and homogenates of chromosome 6+, 20-human-mouse hybrids all affect exogenous ADA-1 in the same way, i.e., by converting it to an ADA tissue isozyme. The evidence therefore indicates that ADCP, on human chromosome 6, is the gene that is responsible for the formation of ADA-d in human tissues, and that its product, an ADA complexing protein, is the same protein present in normal and SCID tissues which combines with ADA-1 to form the tissue isozymes.
DISCUSSION
The molecular identity of each ADA tissue isozyme is apparently determined by the identity of the proteins complexed with the ADA-I enzyme (6, 9) . Since each of the five ADA tissue isozymes has a characteristic electrophoretic mobility, the complexing proteins must be different in each isozyme. There are two possible genetic explanations for the origin of the different ADA complexing proteins. The tissue-specific complexing proteins could be the products of separate genes or the variably modified product of a single gene. Evidence for the latter possibility comes from the observation that neuraminidase treatment of tissue extracts decreases the mobility of ADA-a, -b, and -c to that of ADA-d (27) . This suggests that ADA-d is the initial, or least modified, form of the complex of ADA-1 and ADA complexing protein (27) . Neuraminidase has no effect on the electrophoretic mobility of ADA-1. Thus, the complexing proteins of all of the ADA tissue isozymes may have the same primary structure, while the differences in the electrophoretic mobilities of the tissue isozymes reflect the different degrees of glycosylation of the complexing protein. Since the ADA complexing protein is necessary for assembly of ADA-d, it is probable that processed ADA complexing protein also functions in the assembly of ADA-a, -b, and -c. Processing enzymes, perhaps of the same kind that modify ADA complexing protein, are also involved in the post-translational modification of other enzymes, since ADA-d is one of several enzymes with an altered electrophoretic mobility in mucolipidosis 11(15) , a rare and fatal genetic disease. The primary defect in mucolipidosis II is thought to be in a post-translational step common to the biogenesis of the affected enzymes since some of the electrophoretic abnormalities, including that of ADA-d, can be corrected in vitro by neuraminidase treatment (15 A mechanism similar to that proposed above for the generation of ADA tissue isozymes also operates in the distribution of f3-glucuronidase activity between lysosomes and microsomes in mouse liver (28) . In most strains of mice, a complexing glycoprotein, designated egasyn, combines with lysosomal f3-glucuronidase to form microsomal fl-glucuronidase (4) . The attachment of fl-glucuronidase enzymatic activity to the membrane requires egasyn (28) . Also, GUS and Eg, the structural gene for egasyn, are unlinked (28), as are ADCP and ADA.
ADCP and ADA are under independent genetic control in human-rodent hybrids and in human cells. This is demomstrated by the continued synthesis of ADA complexing protein in the absence of ADA-I in SCID fibroblasts and chromosome 6+, 20-human-mouse hybrids, while human erythrocytes and chromosome 6-, 20+ human-rodent hybrids contain ADA-1 but not ADA complexing protein. Since ADA-1 is required for the expression of ADA activity (6, 29) , the ubiquitous presence of this activity in human cells (1) defines ADA as a constitutively expressed gene. The expression of ADCP, on the other hand, reflects the requirement of a particular cell type for the appropriate distribution of ADA activity between ADA-1 and the ADA tissue isozymes, and probably occurs in response to the signals that accompany cellular differentiation. These signals presumably also effect the synthesis of enzymes that modify ADA complexing protein in a tissue-specific fashion (27) . The significance of ADCP, then, assigned here to human chromosome 6, is its ability to function in the elaboration of a differentiated phenotype: the expression of the ADA tissue isozymes.
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